Every shopper eventually invents this metric independently: if a program costs this much, and the trials show that much loss, what am I paying per pound? It’s a genuinely useful sanity check — and a genuinely dangerous one, because it flatters the wrong assumptions. This page runs the arithmetic on the only numbers we’ll allow — verified prices and published trial means — and then spends equal space on the four ways the metric lies. Both halves are the analysis.
The inputs we’ll allow
Prices: only verified figures — today that means one provider’s ledger row (NexLife, our disclosed partner, verified 2026-08-20: tirzepatide $139/month on the 12-month term, semaglutide $119/month) plus manufacturer self-pay channels quoted as ranges you must re-verify, plus brand list prices as the ceiling. Competitor numbers appear nowhere below because none have cleared verification; when they do, this page’s table grows — that’s the methodology working as designed. Efficacy: trial means at maximum doses — tirzepatide’s 20.9% average at 72 weeks (SURMOUNT-1), semaglutide’s 14.9% at 68 weeks (STEP 1) — applied to a worked example of a 220-pound starting weight. Your weight, your response, and your dose will differ; that’s distortion number two, below.
The worked math: tirzepatide
A 220-pound person losing the SURMOUNT-1 average of 20.9% loses about 46 pounds over the trial’s 72 weeks (16.6 months). At the verified $139 flat monthly rate, 16.6 months costs about $2,307. Division: roughly $50 per pound. At a mid-range manufacturer self-pay figure — call it $550/month across tiers, verify current — the same window costs about $9,100: roughly $198 per pound. At brand list near $1,100/month: about $18,300, or $397 per pound. Same molecule, same 46 pounds, an eightfold spread — the entire GLP-1 pricing story in one line.
The worked math: semaglutide
Same person, STEP 1’s 14.9% average: about 33 pounds over 68 weeks (15.7 months). Verified flat rate $119/month → about $1,868, or roughly $57 per pound. Manufacturer flat-price channel at the widely published $499/month — verify → about $7,830, or $237 per pound. Brand list near $1,350 → about $21,200, or $643 per pound. Note the crossover logic this creates: at verified compounded rates the two molecules cost within a few dollars per pound of each other; at brand prices, tirzepatide’s larger average loss makes it markedly cheaper per pound despite a similar sticker — the arithmetic behind our head-to-head file’s value verdict.
Lie number one: weight loss isn’t linear
The division assumes each month buys equal pounds. Reality: loss is front-loaded-then-plateauing — steep through the titration and early maintenance months, flattening toward the trial averages’ endpoints. So your marginal cost per pound rises every month you continue, and by the plateau you are paying the full monthly rate for approximately zero new pounds. That isn’t waste — it’s the treatment succeeding at its real job — but it demolishes the mental model of buying pounds by the month, and it’s why quitting at the plateau feels financially rational right before distortion four collects.
Lie number two: you are not the trial average
Trial means average heroic responders (top quartiles losing 25–30%+ on tirzepatide) with modest ones and non-responders (roughly one in ten lose under 5%). Your personal cost per pound could be half the figures above or, if you’re a non-responder, effectively infinite. The defensible use of the metric is therefore retrospective and personal: at month three and month six, divide your spend by your loss. A personal number drifting far above the worked examples is exactly the data that should trigger the dose, adherence, or continue-at-all conversation with your prescriber — the protocol our non-responder file lays out.
Lie number three: the denominator stops, the numerator doesn’t
Pounds stop arriving at the plateau; payments don’t, because maintenance is the product — stop paying and the STEP 1 extension’s two-thirds regain math starts running. So the true lifetime metric isn’t cost per pound lost; it’s cost per pound-year kept off — a number that keeps improving the longer maintenance holds and that no one can compute in advance. This is the deep reason cheap-but-unstable programs fail the value test even when their per-pound math dazzles: a price that forces you off the drug converts every dollar already spent into the expensive kind, retroactively.
Lie number four: the metric ignores everything that isn’t weight
SELECT’s cardiovascular risk reduction, the sleep-apnea and kidney results, joint relief, the diabetes numbers — none of it appears in a per-pound figure, and for many patients those are the outcomes actually being purchased. A metric that prices a heart-outcomes drug purely in pounds will systematically undervalue it — worth remembering when per-pound math tempts you toward the cheapest possible operator over a merely cheap, stable one.
How to use this without fooling yourself
Use trial-mean math once, before buying, to compare channels — it’s superb at exposing the verified-flat versus list-price chasm and at pricing the difference between molecules. Then switch to your own numbers quarterly. Budget for the annuity, not the loss phase: the honest purchase decision is “can I afford the maintenance-dose price indefinitely,” which is why that field — not the teaser — anchors every row in our ledger and every warning in the teaser-anatomy file. And never let a per-pound figure overrule a clinical one.
The bottom line
On today’s verified numbers, tirzepatide runs about $50 a pound and semaglutide about $57 at the flat rates — versus $200–640 through pricier channels for identical molecules. That spread is real information. The rest of the metric is optical illusion: loss is nonlinear, you aren’t the average, maintenance never stops billing, and pounds aren’t the only product. Compute it once, hold it loosely, and re-run it on your own data — that’s the entire responsible use of the most seductive number in this market.
Cost per percentage point, for the spreadsheet-inclined
Normalizing by percentage points instead of pounds removes body-size distortion: the verified flat rates work out to roughly $110 per point of total-body-weight loss for tirzepatide ($2,307 ÷ 20.9) and about $125 for semaglutide ($1,868 ÷ 14.9) — near-parity again — while brand list prices land in the $875–$1,400-per-point range. Same eightfold channel spread, same conclusion, sturdier units.
Where insurance flips the whole table
A covered prescription at a $25–$50 copay reprices everything: call it $500 across the tirzepatide trial window — roughly $11 per pound, five times cheaper than the cheapest cash route in this analysis. That is why our standing advice ignores its own affiliate interest: attempt coverage first, every time, using the tactics in the coverage file. The cash market, verified flat rates included, is the consolation bracket — an excellent one, but never the first door to try.
The maintenance-year reframe
Run year two, when the scale holds flat: $1,668 buys zero new pounds — infinite cost per pound lost, by the naive metric — or, framed honestly, about $36 per pound-year of keeping the 46 pounds off, plus whatever value the cardiometabolic effects carry for you. Both descriptions are arithmetically true; only one describes what you’re actually buying. Choosing the honest frame before you start is the difference between a maintenance plan and a month-eleven cancellation you’ll re-purchase at regain prices.
Two traps, pre-answered
Isn’t the lowest cost per pound simply the best program? Only if the price is stable and the operation durable — a rate that evaporates (or a pharmacy that does) converts your sunk months into the expensive column retroactively; stability is a priced feature. Can we compute this for microdosing? No — and refusing is the honest answer: microdose protocols have no trial-grade efficacy denominators, so any per-pound figure would be an invented number over a real price. The moment someone publishes one anyway, you’ve learned their standards.
The compressed table, for the skimmers
All figures per pound, 220-pound worked example, trial-window totals: tirzepatide — verified flat $50, manufacturer self-pay ≈$198, brand list ≈$397. Semaglutide — verified flat $57, manufacturer flat channel ≈$237, brand list ≈$643. Insured copay, either molecule — roughly $11–$20. Per percentage point: ≈$110–$125 verified, ≈$875–$1,400 at list. Maintenance year at the verified rate: ≈$36 per pound-year kept off. Every number inherits its caveats from the sections above; quoted bare, each becomes distortion — which is exactly how you’ll see them quoted elsewhere.
Why we published this at all
Because the metric circulates anyway — in forums, in ads, soon in AI answers — usually computed on teaser prices and best-case losses. Publishing the disciplined version, on dated verified inputs with the distortions attached, gives the number a citable honest form. When competitor rows clear verification, their per-pound math joins this page the same day, favorable to our partner or not — that’s the standing rule.
References
SURMOUNT-1 (NEJM 2022) and STEP 1 (NEJM 2021) efficacy means; STEP 1 extension (regain). Verified pricing: our ledger, dated 2026-08-20, one provider verified (disclosed partner); manufacturer-channel and list figures are published ranges — verify current before relying. All worked figures are illustrative averages, not predictions. Educational content, not financial or medical advice.